Cited by 110Chronic Obstructive Pulmonary Disease (COPD) ResearchRespiratory viral infections researchAsthma and respiratory diseases

Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations

Open access
De Serres, Gaston, Lampron, Noël, La Forge, Jacques, Rouleau, Isabelle, Bourbeau, Jean, Weiss, Karl, Barret, Béatrice, Boivin, Guy·2009·Journal of Clinical Virology

Abstract

Background Few studies have evaluated the contribution of both viruses and bacteria in acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Objectives This study estimated the burden of both types of pathogens among adults seeking care for an AECOPD during two consecutive winter seasons.Study design Patients 50 years or older who consulted within 10 days of AECOPD onset were eligible. Clinical data were collected on a standardized questionnaire, and nasopharyngeal aspirates (NPA), paired sera, and non-induced sputum were collected. Polymerase chain reaction (PRC) assays were used to identify viral, atypical and bacterial pathogens in NPA specimen.Results Overall, 108 patients with AECOPD were included, 88% of patients were admitted and 2 patients (2%) received intensive care. A third of patients (31%) had evidence of a viral infection, 9% with influenza A, 7% RSV and 7% with PIV-3. One patient was positive for Mycoplasma pneumoniae. Bacterial pathogens were identified in 49% of patients with available sputum, most frequently Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae. Among virus-infected patients, 14 (58%) also had bacteria in their sputum, but co-infected patients did not present with different symptoms than patients with single infections.Conclusions These results suggest that influenza and RSV are frequent contributors of AECOPD, and that coinfection with bacteria does not appear to be more severe among virus-infected patients. Clinicians should be aware that AECOPD may be frequently triggered by viruses, and may consider antivirals and proper infection control measures in appropriate epidemiological setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcv.2009.07.010

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Human metapneumovirus and the V protein of parainfluenza virus 5 block IFN signaling by inhibiting or degrading STAT-1.

    “Human metapneumovirus and the V protein of parainfluenza virus 5, for instance, block IFN signaling by inhibiting or degrading STAT-1 (47, 329).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
De Serres, G., Lampron, N., La Forge, J., Rouleau, I., Bourbeau, J., Weiss, K., Barret, B., & Boivin, G.
Affiliations
  • Centre hospitalier universitaire de Québec (CA)
  • Montreal Chest Institute (CA)
  • Hôpital Maisonneuve-Rosemont (CA)
  • Sanofi (France) (FR)
  • Centre hospitalier de l'Université Laval (CA)
Venue
Journal of Clinical Virology
Publisher
Elsevier BV
Published
2009-10
Volume
46
Issue
2
Pages
129-133
ISSN
1386-6532 (ISSN-L)
OpenAlex
W2051682127
Cited by
108
References
32
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 2 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 16 · 2014: 5 · 2013: 10 · 2012: 8
FWCI
8.14
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Virology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Sanofi Pasteur
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
COPD exacerbations, viral infection, bacterial infection, influenza A virus, respiratory syncytial virus, parainfluenza virus type 3, Mycoplasma pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, co-infection, winter
MeSH terms
Aged, Bacterial Infections, Female, Humans, Influenza, Human, Male, Middle Aged, Influenza A virus, Respiratory Syncytial Viruses, Respiratory Tract Infections, Risk Factors, Sputum, Virus Diseases, Respiratory Syncytial Virus Infections, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review